Author

E. Jókai

Observed names: Eniko Jokai, Enikő Jokai, Enikő Jókai

Institution: Gedeon Richter (Hungary)

Observed institution: Gedeon Richter (Hungary)

ORCID: 0000-0002-5066-8231

Observed ORCID: 0000-0002-5066-8231

OpenAlex ID: A5086421588

The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study

2018 · I. Takács, E. Jókai, et al. · Osteoporosis International · 20

A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis

2025 · Lothar Seefried, Serge Ferrari, et al. · Osteoporosis International · 5

Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase

2026 · Serge Ferrari, Lothar Seefried, et al. · Osteoporosis International · 1

A Randomized Phase 1 Study Comparing the PK , PD , Safety, and Immunogenicity of Proposed Biosimilar RGB ‐14‐X and Denosumab in Healthy Adult Males

2026 · Emmanuel Biver, Jean‐Jacques Body, et al. · Clinical and Translational Science · 1

Investigating Factors Influencing the Long-Term Outcome of Teriparatide Treatment on the Risk of Hip Fracture. Is sequential treatment essential?

2026 · Szilvia Meszaros, Balazs Szili, et al. · Journal of Bone and Mineral Research

2910P A multicentre, randomised, double blind, phase I study comparing the pharmacokinetics and pharmacodynamics of proposed biosimilar RGB-14-X and reference denosumab in healthy adult males

2025 · E. Biver, J-J. Body, et al. · Annals of Oncology

Risk of non-completion of sequential osteoporosis therapy after teriparatide treatment - real-life data from Hungary

2025 · Istvan Takacs, Boglarka Szabo, et al. · Endocrine Abstracts

Works count: 7

Citation count: 27

H-index: 2

I10-index: 1